Pharmena S.A. (PHR.WA)
PLN 4.0
(-3.15%)
PLN 4.0
(-3.15%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.9 Million PLN | -90.16% |
| 2022 | 19.37 Million PLN | 19.04% |
| 2021 | 16.27 Million PLN | 44.03% |
| 2020 | 11.29 Million PLN | 67.53% |
| 2019 | 6.74 Million PLN | 38.57% |
| 2018 | 4.86 Million PLN | -35.47% |
| 2017 | 7.54 Million PLN | -9.57% |
| 2016 | 8.34 Million PLN | 28.6% |
| 2015 | 6.48 Million PLN | 71.61% |
| 2014 | 3.77 Million PLN | 50.8% |
| 2013 | 2.5 Million PLN | -3.98% |
| 2012 | 2.61 Million PLN | 63.31% |
| 2011 | 1.59 Million PLN | 75.05% |
| 2010 | 912.97 Thousand PLN | -2.34% |
| 2009 | 934.88 Thousand PLN | 27.15% |
| 2008 | 735.25 Thousand PLN | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.41 Million PLN | -25.6% |
| 2024 Q2 | 1.2 Million PLN | -14.74% |
| 2023 Q2 | 59.49 Million PLN | 200.76% |
| 2023 Q1 | 19.78 Million PLN | 2.11% |
| 2023 Q4 | 1.9 Million PLN | -46.63% |
| 2023 Q3 | 3.57 Million PLN | -94.0% |
| 2023 FY | 1.9 Million PLN | -90.16% |
| 2022 Q3 | 19.11 Million PLN | 16.85% |
| 2022 Q1 | 15.66 Million PLN | -3.73% |
| 2022 FY | 19.37 Million PLN | 19.04% |
| 2022 Q4 | 19.37 Million PLN | 1.36% |
| 2022 Q2 | 16.35 Million PLN | 4.41% |
| 2021 Q2 | 14.71 Million PLN | 9.31% |
| 2021 Q4 | 16.27 Million PLN | 5.25% |
| 2021 FY | 16.27 Million PLN | 44.03% |
| 2021 Q1 | 13.45 Million PLN | 19.13% |
| 2021 Q3 | 15.46 Million PLN | 5.08% |
| 2020 Q3 | 10.13 Million PLN | 13.11% |
| 2020 Q4 | 11.29 Million PLN | 11.46% |
| 2020 Q2 | 8.96 Million PLN | 24.7% |
| 2020 Q1 | 7.18 Million PLN | 6.55% |
| 2020 FY | 11.29 Million PLN | 67.53% |
| 2019 Q3 | 6.43 Million PLN | -12.03% |
| 2019 Q1 | 13.06 Million PLN | 168.34% |
| 2019 Q4 | 6.74 Million PLN | 4.82% |
| 2019 FY | 6.74 Million PLN | 38.57% |
| 2019 Q2 | 7.31 Million PLN | -44.0% |
| 2018 Q2 | 5.16 Million PLN | -5.59% |
| 2018 FY | 4.86 Million PLN | -35.47% |
| 2018 Q4 | 4.86 Million PLN | -25.16% |
| 2018 Q3 | 6.5 Million PLN | 25.93% |
| 2018 Q1 | 5.47 Million PLN | -27.47% |
| 2017 Q4 | 7.54 Million PLN | 20.1% |
| 2017 Q3 | 6.28 Million PLN | -11.07% |
| 2017 Q1 | 7.39 Million PLN | -11.39% |
| 2017 FY | 7.54 Million PLN | -9.57% |
| 2017 Q2 | 7.06 Million PLN | -4.44% |
| 2016 Q1 | 5.62 Million PLN | -13.31% |
| 2016 Q2 | 7.39 Million PLN | 31.57% |
| 2016 Q4 | 8.34 Million PLN | 8.99% |
| 2016 FY | 8.34 Million PLN | 28.6% |
| 2016 Q3 | 7.65 Million PLN | 3.45% |
| 2015 Q2 | 6.35 Million PLN | 55.28% |
| 2015 Q1 | 4.09 Million PLN | 8.28% |
| 2015 FY | 6.48 Million PLN | 71.61% |
| 2015 Q4 | 6.48 Million PLN | -7.13% |
| 2015 Q3 | 6.98 Million PLN | 9.9% |
| 2014 Q2 | 3.14 Million PLN | -5.58% |
| 2014 FY | 3.77 Million PLN | 50.8% |
| 2014 Q4 | 3.77 Million PLN | 11.51% |
| 2014 Q3 | 3.38 Million PLN | 7.66% |
| 2014 Q1 | 3.33 Million PLN | 33.04% |
| 2013 Q1 | - PLN | -100.0% |
| 2013 FY | 2.5 Million PLN | -3.98% |
| 2013 Q3 | 1.96 Million PLN | 0.0% |
| 2013 Q4 | 2.5 Million PLN | 27.79% |
| 2012 FY | 2.61 Million PLN | 63.31% |
| 2012 Q4 | 2.61 Million PLN | 0.0% |
| 2011 FY | 1.59 Million PLN | 75.05% |
| 2010 FY | 912.97 Thousand PLN | -2.34% |
| 2009 FY | 934.88 Thousand PLN | 27.15% |
| 2008 FY | 735.25 Thousand PLN | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Bioceltix S.A. | 2.26 Million PLN | 15.983% |
| BIOTON S.A. | 215.86 Million PLN | 99.117% |
| Captor Therapeutics Spolka Akcyjna | 28.07 Million PLN | 93.211% |
| Mabion S.A. | 90.47 Million PLN | 97.893% |
| Molecure S.A. | 11.34 Million PLN | 83.199% |
| NanoGroup S.A. | 1.49 Million PLN | -27.911% |
| Poltreg S.A. | 39.58 Million PLN | 95.185% |
| Pure Biologics Spólka Akcyjna | 20.84 Million PLN | 90.856% |
| Ryvu Therapeutics S.A. | 120.36 Million PLN | 98.416% |
| Synthaverse S.A. | 153.26 Million PLN | 98.756% |
| Urteste S.A. | 1.85 Million PLN | -2.749% |